- Home
- CRVO vs AVTX Comparison
CRVO vs AVTX Comparison
Compare CRVO & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- AVTX
- Stock Information
- Founded
- CRVO 2001
- AVTX 2011
- Country
- CRVO United States
- AVTX United States
- Employees
- CRVO N/A
- AVTX N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- AVTX Health Care
- Exchange
- CRVO Nasdaq
- AVTX Nasdaq
- Market Cap
- CRVO 95.4M
- AVTX 88.4M
- IPO Year
- CRVO N/A
- AVTX 2015
- Fundamental
- Price
- CRVO $8.91
- AVTX $9.01
- Analyst Decision
- CRVO Strong Buy
- AVTX Strong Buy
- Analyst Count
- CRVO 8
- AVTX 7
- Target Price
- CRVO $25.43
- AVTX $34.33
- AVG Volume (30 Days)
- CRVO 13.3M
- AVTX 106.4K
- Earning Date
- CRVO 03-17-2025
- AVTX 05-12-2025
- Dividend Yield
- CRVO N/A
- AVTX N/A
- EPS Growth
- CRVO N/A
- AVTX N/A
- EPS
- CRVO N/A
- AVTX N/A
- Revenue
- CRVO $9,737,974.00
- AVTX $441,000.00
- Revenue This Year
- CRVO N/A
- AVTX N/A
- Revenue Next Year
- CRVO N/A
- AVTX N/A
- P/E Ratio
- CRVO N/A
- AVTX N/A
- Revenue Growth
- CRVO 36.29
- AVTX N/A
- 52 Week Low
- CRVO $1.80
- AVTX $4.60
- 52 Week High
- CRVO $25.92
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- CRVO 63.30
- AVTX 65.26
- Support Level
- CRVO $8.53
- AVTX $6.98
- Resistance Level
- CRVO $16.94
- AVTX $8.30
- Average True Range (ATR)
- CRVO 2.01
- AVTX 0.90
- MACD
- CRVO 0.66
- AVTX 0.16
- Stochastic Oscillator
- CRVO 50.33
- AVTX 90.60
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).